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Th   e Heisenberg uncertainty principle has a great impact 
on medical research by drawing our attention to the bias 
introduced by our experimental tools. In a recent issue of 
Breast Cancer Research, Keller and colleagues [1] report 
an example of this principle: sustained propagation of 
large numbers of cells, through the establishment of cell 
lines, disrupts the normal balance between diﬀ  erentiated 
cells and their progenitors, as observed in fresh biological 
specimens. Th   e work of these authors contributes 
another piece in a contentious ﬁ  eld that combines tissue 
morphology and immuno  histo  chemical phenotypes 
[2,3], molecular classiﬁ  cation of breast cancer tissues [4], 
and cell biological assays aimed at the tumor-initiating 
cell (TIC) phenotype [5]. Sorting cells according to their 
respective cell surface markers, CD44+/CD24−/low, results 
in the enrichment of TIC activities, including mammo-
spheres [6] and trans  plan  ta  tion eﬃ   ciency  in  mouse 
xenografts [7]. Establishing xeno  graft growth could be 
the product of several system-speciﬁ  c selections other 
than breast progenitor phenotypes. However, further 
molecular proﬁ  ling of these cell populations – in which 
CD44+/CD24−/low-sorted cells expressed low levels of 
luminal diﬀ  erentiation markers (such as MUC1, CD24, 
or CDH1) and elevated levels of epithelial-mesenchymal 
transition markers (such as VIM, collagens, TWIST1, 
SNAI1/2, and Zeb1/2) – indicated a link between 
epithelial-mesen  chymal transi  tion, TIC, and basal-like 
[6,8] or claudin-low [9,10]-speciﬁ  c breast cancer mole-
cular subtypes. More recently, however, a more compre-
hen  sive interrogation of pluripotent self-renewal identi-
ﬁ  ed a population high for CD24, or luminal progenitors 
[9,11-13], capable of giving rise to mesenchymal or basal-
like tumors, at least in the context of BrCa1 mutations. 
Given the variability of single markers within single 
individuals, the diﬀ  erent sensitivities each cell biological 
assay presents with, and the consistency across other 
genes (which are more likely to be drivers of the 
phenotypes rather than eﬀ  ective surrogate markers), the 
more recent work presents compel  ling evidence that, 
admittedly, neither CD24 nor CD44 populations are 
homogenous or contain pure diﬀ  erentiated of progenitor 
populations, respectively. A hypothetical linear sequen-
tial diﬀ  erentiation track that would ﬂ  ip back and forth 
with respect to CD24 expression and appear as a hidden 
subpopulation in a majority of cells from another diﬀ  er-
entiation stage could explain this discrepancy. A more 
comprehensive whole-genome mRNA proﬁ  ling analysis 
of the relatedness between luminal progenitors (CD49fhi/
EpCAM+), stem cells (CD49fhi/EpCAM−), and CD44+/
CD24−/low popula  tions is necessary to assess this hypothe-
sis. Th  is point is emphasized by the fact that stem cell 
marker ALDH1 [14] is expressed by only some of the 
cells in either fractions described above yet ALDH1+ cells 
exhibit the greatest TIC capacity.
Th  e underlying hypothesis assumes that, within the 
dynamic steady state of breast epithelial maintenance, 
self-renewal, and diﬀ   erentiation (as it responds to 
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Clinical management of breast cancer relies on case 
stratifi  cation, which increasingly employs molecular 
markers. The motivation behind delineating breast 
epithelial diff  erentiation is to better target cancer 
cases through innate sensitivities bequeathed 
to the cancer from its normal progenitor state. A 
combination of histopathological and molecular 
classifi  cation of breast cancer cases suggests a role for 
progenitors in particular breast cancer cases. Although 
a remarkable fraction of the real tissue repertoire 
is maintained within a population of independent 
cell line cultures, some steps that are closer to the 
terminal diff  erentiation state and that form a majority 
of primary human breast tissues are missing in the cell 
line cultures. This raises concerns about current breast 
cancer models.
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© 2011 BioMed Central Ltdlactation-related breast augmentation) and the successive 
involution, cancer arises from speciﬁ  c  intermediary 
states and somehow maintains the molecular proﬁ  le of its 
cell of origin [15]. It is indeed remarkable that breast 
cancer cell lines can be subdivided into the same 
molecular subtypes as primary cancer [16]. However, 
these observations are good in only ﬁ  rst-degree 
approximation since molecular proﬁ  ling of tissue whole 
mass cannot capture the incredible heterogeneity of 
cancer populations [17]. Although cellular heterogeneity 
severely hinders our ability to assign stem cell phenotype 
and markers on the single-cell level, recent advances in 
expression proﬁ  ling of single cells [18] may shed more 
light on this mystery. Nevertheless, population analysis 
still informs our under  standing of TIC markers. By 
employing ﬂ  uorescence-activated cell sorting (FACS) and 
carefully appraising each marker, Keller and colleagues 
[1] ﬁ  nd that CD44 is a relatively promiscuous marker 
whereas EpCAM, CD24, and CD49f demonstrate 
extensive heterogeneity within cultured populations of 
the investigated cell lines. Interpreting these results in 
terms of self-renewal and morphological phenotypes 
(such as mammosphere and xenograft growth eﬃ   ciency) 
or mesenchymal appearance further demonstrated the 
complexity of diﬀ  erentiation states, as judged by a hand-
ful of markers. Th  e authors benchmark the progenitor 
cell population by assuming that the overall self-renewal 
phenotype of a given cell line’s mixed population should 
correlate with the abundance of the particular population 
allegedly capable of the self-renewal. Further support to 
their cell fraction-self-renewal assignment is still needed 
from direct cell population subfractionation by using 
FACS similar to that performed by Al-Hajj and colleagues 
[7].
Stem cell ‘puriﬁ   cation’ may gain insight from a 
biochemical puriﬁ   cation scheme, in which successive 
fractionation results in diminishing yields and increasing 
speciﬁ  c activity. For example, consider the puriﬁ  cation of 
mitosis-promoting factor (MPF). For a long time, 
conﬂ  icting reports claimed that MPF depends on or is 
attenuated by phosphatase activity. Ultimately, it was 
recog  nized that the activity was dependent, in a sequen-
tial fashion, on both the kinase activity of MPF and the 
phosphatase activity of CDC25. It is agreed that, in 
normal tissue, progenitors are regulated by signals from 
their respective niche. However, assays for the activity of 
self-renewal, which not only mimic the niche more 
eﬀ   ectively but potentially involve mixing back the 
isolated cells with other cell populations at the onset of 
the assay (much to the same eﬀ  ect as mixing homogenous 
basal transcription factors in an in vitro reconstituted 
transcription reaction), have not yet been employed. 
Consequently, as was the case for MPF, it is possible that 
all current reports rely on mixed populations. In support 
of this notion, the claudin-low candidate TIC-like cancers 
are also elevated with leukocyte inﬁ  ltrate signature [10], 
which could reﬂ  ect the role of heterotypic interactions 
that regulate progenitor phenotype in vivo, but not in 
current model systems. Such rigorous reconstitution 
experiments, with trackable cell progeny, may oﬀ  er new 
handles with which to control, rather than monitor, 
breast stem cells.
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